- Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on 
May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc. 
("Rosvivo"), an American new drug developer, for about 5.5 million U.S. dollars.

As a result, Nexturn Bio Inc. strengthens its capabilities as a bio-company by 
cooperating in the development of new medication pipelines utilizing miRNA 
technology to target diabetes, obesity, non-alcoholic fatty liver disease 
(NAFLD), gastrointestinal (GI) dysmotility, and COVID-19.

Nexturn Bio Inc. decided to invest in RosVivo and its miRNA technology through 
due diligence and valuation by industry-leading law firms, patent corporations, 
strategy consulting firms, and domestic and overseas accounting firms. Nexturn 
also consulted with multiple key opinion leaders in endocrinology and 
gastroenterology and received positive feedback regarding the efficacy of the 
new drug.

According to a market report from Global Market Insights, the global diabetes 
drugs market was valued at about $65.5 billion (USD) in 2019. The top global 
pharmaceutical companies such as AstraZeneca, Novo Nordisk, Eli Lilly, and 
Sanofi have  increased revenue by participating in the early stage development 
of diabetes drugs. This corresponds to an April 2020 study by GoodRx, an 
American telemedicine platform providing comparisons of prescription drug 
prices, which described diabetes as an expensive chronic disease. A diabetic 
patient spends approximately an average of $222 and $476 per month for 
non-insulin and insulin drugs.

However, regardless of this high out-of-pocket expense, conventional diabetes 
drugs today still have not solved the problem of frequent administration and 
various side effects. Many diabetic treatments depend on alleviating symptoms, 
which is temporarily effective. Thus, developing a drug to treat the 
fundamental cause of diabetes is urgently needed. 

RosVivo's new miRNA drug RSVI-301 significantly reduces injection frequency, 
showed a prolonged effect, and alleviated side effects such as GI dysmotility 
in animal studies. It is expected that RSVI-301 will become a first-in-class 
diabetic drug. 

"We consider this project not only as a successful investment, but also as a 
great opportunity to develop an innovative diabetic treatment in collaboration 
with RosVivo," said an official at Nexturn Bio Inc. "We will do our best to 
demonstrate the market potential of RosVivo's miRNA-based pipelines as an 
innovative anti-diabetic medication."

In addition to the anti-diabetic pipeline, RSVI-301, RosVivo is planning to 
collaborate with established universities and healthcare institutions to start 
clinical trials for RosVivo's other treatment pipeline named RSVI-305/306, 
which will target COVID-19.

SOURCE   NEXTURN Bio Inc.


Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=392009

   Caption: Global Antidiabetics Pharma Companies and drugs